FDA approves Hizentra for chronic inflammatory demyelinating polyneuropathy.- CSL Behring.
The FDA has approved Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) from CSL Behring, as a subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. The approval was based on data from the Phase III PATH (Polyneuropathy And Treatment with Hizentra) study, which is the largest controlled clinical study in CIDP patients to date. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage.
The PATH study demonstrated that the percentage of patients experiencing CIDP relapse or withdrawal for any other reason during SCIg treatment was significantly lower with Hizentra (38.6 percent on low-dose Hizentra [0.2 g/kg weekly]; 32.8 percent on high-dose Hizentra [0.4 g/kg weekly]) than with placebo (63.2 percent). Additionally, the PATH study demonstrated that patients on Hizentra reported fewer systemic adverse reactions (ARs) per infusion compared to IVIg treatment (2.7 percent versus 9.8 percent, respectively). In fact, 93 percent of the 4,225 total Hizentra infusions were free of any ARs.